You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: ENGINEERING RESOURCES GROUP INC            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Rodent Research Home Cage Monitoring System for Animal Welfare

    SBC: TRICORDER ARRAY TECHNOLOGIES LLC            Topic: 100

    PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. microRNA-21 Blockade of Triple Negative Breast Cancer

    SBC: BOUND THERAPEUTICS LLC            Topic: 102

    Triple negative breast cancerTNBCis an orphan disease that attacksUS women every yearTNBC cells lack human estrogen receptorprogesterone receptorand epidermal growth factor receptorHerthe targets of existing medicinesTNBC recurs after standard of care chemotherapy and radiationkilling its victims withinyearsNew promising therapies such as poly ADP ribosepolymerasePARPinhibitors only benefit a smal ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.

    SBC: EARNANO LLC            Topic: NICHD

    Otitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Portable Device for Accurate Mouse Tail Vein Injection

    SBC: Technology Commercialization Partners LLC            Topic: OD

    PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. PreImplantation Factor plus hypothermia to treat neonatal brain injury

    SBC: BioIncept, LLC            Topic: NICHD

    ABSTRACTPerinatal hypoxic ischemic encephalopathyHIEaffectstoinfants per everybornMortality from HIE can be up toand approximatelyof survivors suffer significant longterm disability including cerebral palsyepilepsyand developmental disordersDamage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brainHoweverincreasing evidence indicates that secondary and tertiary ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government